Evidence map›Paper›PMID 42809016›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

PD-L1 PET/CT imaging with

Jasper Smit, Frank J Borm, Nienke R Gerards, Sanne E Wiegers, Daniel Holden, David Leung, Diederik J Grootendorst, Bert Windhorst, Nabeel Nabulsi, Zhengxin Cai and 6 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03001882 (An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in Combination With Ipilimumab in Subjects With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03001882 phase2completednot on this map

An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in Combination With Ipilimumab in Subjects With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

TypeinterventionalSponsorBristol-Myers SquibbRan2017 to 2023Enrolled230ConditionsNon-Small Cell Lung CancerArmsNivolumab, Ipilimumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jasper SmitDepartment of Thoracic Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. ja.smit@nki.nl.ORCID http://orcid.org/0009-0002-8233-1307
Frank J BormDepartment of Thoracic Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.
Nienke R GerardsDepartment of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers (VU University Medical Center), Amsterdam, The Netherlands.
Sanne E WiegersDepartment of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers (VU University Medical Center), Amsterdam, The Netherlands.
Daniel HoldenDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.
David LeungBristol-Myers Squibb Research and Development, Route 206 & Province Line Rd, Princeton, NJ, 08543, USA.
Diederik J GrootendorstBristol-Myers Squibb Research and Development, Route 206 & Province Line Rd, Princeton, NJ, 08543, USA.
Bert WindhorstDepartment of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers (VU University Medical Center), Amsterdam, The Netherlands.
Nabeel NabulsiDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.
Zhengxin CaiDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.
Yiyun HuangDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.
Richard E CarsonDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.
Scott GettingerDepartment of Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Egbert F SmitDepartment of Pulmonary Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Ronald BoellaardDepartment of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers (VU University Medical Center), Amsterdam, The Netherlands.
Adrianus J de LangenDepartment of Thoracic Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands.

Funding

Bristol-Myers Squibb Bristol-Myers Squibb
6 · The paper itself

Abstract

purposePredicting response to checkpoint inhibitors in non-small cell lung cancer (NSCLC) remains challenging. In addition to programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC), PD-L1 imaging could improve response prediction. This study evaluated a novel PD-L1 PET tracer,

methodsStage IV NSCLC patients were scheduled for baseline PET/CT scans with both tracers. Tracer uptake was quantified using SUVpeak and SUVmean. Imaging findings were correlated with PD-L1 expression from tumor biopsies and clinical outcomes, including best overall response and overall survival.

results

conclusionCLINICAL

trial registrationNCT03001882, https//clinicaltrials.gov/study/NCT03001882.

Indexed as

ImmunotherapyNSCLCPD-L1 imagingPET/CT

Identifiers

PMID42809016

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.